Madrigal revenue surges on Rezdiffra success despite earnings miss
Madrigal Pharmaceuticals (NASDAQ:MDGL), the West Conshohocken, Pennsylvania-based leader in liver disease therapies, reported fourth-quarter revenue that outpaced Wall Street estimates, driven by the explosive commercial trajectory of its flagship MASH treatment, Rezdiffra.























